Nevertheless, SGLT-2 inhibitors are known for weight loss, visceral adipose reduction, improved glucose control, and cardioprotection pointing toward the therapeutic potential for NAFLD [56]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.